Further, the progress in antibody engineering has led to development of dual targeting antibodies, or bispecific antibodies which have the ability to target two different antigens simultaneously. Currently, only few bispecific antibody constructs have been developed including PF-07257876, HX009, BAT7104,...
(R/M HNSCC). The AK117-302 study represents a significant milestone as the first Phase III clinical trial globally to investigate a CD47 monoclonal antibody therapy for solid tumors. This trial is the fifth Phase III study for ivonescimab, utilizing PD-1/L1 monoclonal antibody therapy as a ...
Office line: + 86 21 6039 8363 View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-reports-phase-1-clinical-trial-data-of-highly-differentiated-anti-cd47-monoclonal-antibody-lemzoparlimab-at-the-2020-sitc-annual-meeting-301168649.html S...
Given that radiotherapy is a common treatment option for patients with SCLC and that several clinical trials to test anti-CD47 antibody efficacy against hematologic malignancies and solid tumors are ongoing51,52,53,54, our preclinical findings could be readily tested in the clinic in patients with ...
Antibody humanization is important for reducing the immunogenic responses associated with animal-derived antibodies. Numerous antibodies are commercialized as therapeutics, however, the immunogenicity of animal-derived antibodies may restrict their application in clinical. According to previous research [52], ...
Here, we describe a combination strategy of black phosphorus (BP)-based photothermal therapy together with anti-CD47 antibody (aCD47)-based immunotherapy to synergistically enhance cancer treatment. Tumour resistance to immune checkpoint blockades in mos
cells use to evade phagocytosis, we engineered a B-LNP that is functionalized with (i) anti-CD47 antibody (αCD47), allowing for targeting and blocking of overexpressed CD47 in gliomas, as well as (ii) anti-PD-L1 antibody (αPD-L1) for binding and engaging of TAMCs to glioma cells (...
The CD47 antibody is commonly used in clinical trials for lymphomas, and its anti-tumor activity depends on the IgG subtype, which binds FcγR to active Fc-mediated functions. The fully human antibody has lower immunogenicity and higher safety than humanized antibody, but side effects such as ...
clinical trials [107,108,109,110]. Targeting CD47 to disrupt its interaction with SIRPα can enhance the immune system’s ability to destroy cancer cells and could be explored to prevent autoinflammatory diseases. Anti–neutrophil cytoplasmic antibody (ANCA)–associated vasculitis is an ...
loaded with anti-CD47 antibody (aCD47), is composed of SPC and GDO with a mass ratio of 50/50, and has a much higher phase transition temperature of 92 °C (Fig. S1). It will hydrate at a later stage and maintain the gel state for a much longer time, enabling the sustained releas...